5-methoxydithiosalicylic acid di-2-chloroethyl amide | 793725-10-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-methoxydithiosalicylic acid di-2-chloroethyl amide
• 英文别名: N-(2-chloroethyl)-2-[[2-(2-chloroethylcarbamoyl)-4-methoxyphenyl]disulfanyl]-5-methoxybenzamide
• CAS: 793725-10-7
• 化学式: C₂₀H₂₂Cl₂N₂O₄S₂
• 分子量: 489.444
• InChiKey: CKQITQQADCBMAW-UHFFFAOYSA-N

物化性质

• 沸点：
  630.0±55.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  30
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  127
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-methoxydithiosalicylic acid di-2-chloroethyl amide 以80的产率得到3,4-二氢-7-甲氧基苯并[f][1,4]硫氮杂卓-5(2H)-酮
  参考文献：
  名称：

  Novel agents for preventing and treating disorders involving modulation of the RyR receptors

  摘要：

  本发明提供了式I的新化合物及其盐、水合物、溶剂合物、配合物和前药。本发明还提供了合成式I化合物的方法。此外，本发明还提供了包含式I化合物的制药组合物和使用该制药组合物治疗和预防与细胞中调节钙离子通道功能的RyR受体相关的疾病和疾病的方法。这些疾病和疾病包括，例如，心脏疾病和疾病，骨骼肌疾病和疾病，认知障碍和疾病，恶性高热，糖尿病和婴儿猝死综合征。心脏疾病和疾病包括但不限于心律不齐疾病和疾病；运动引起的心律不齐疾病和疾病；猝死；运动引起的猝死；充血性心力衰竭；慢性阻塞性肺疾病；高血压。心律不齐疾病和疾病包括运动引起的心律不齐疾病和疾病，但不限于心房和心室心律失常；心房和心室颤动；心房和心室快速心律失常；心房和心室快速心跳；儿茶酚胺多形性心室心动过速（CPVT）；及其运动引起的变异。骨骼肌疾病和疾病包括但不限于骨骼肌疲劳，运动引起的骨骼肌疲劳，肌萎缩症，膀胱疾病和失禁。认知障碍和疾病包括但不限于阿尔茨海默病，记忆丧失的形式和年龄相关的记忆丧失。

  公开号：

  US20070049572A1
• 作为产物：
  描述：

  2-氯乙胺 在 氯化亚砜 作用下， 以90%的产率得到5-methoxydithiosalicylic acid di-2-chloroethyl amide
  参考文献：
  名称：

  Novel agents for preventing and treating disorders involving modulation of the RyR receptors

  摘要：

  本发明提供了Formula I的新化合物及其盐、水合物、溶剂合物、络合物和前药。本发明还提供了合成Formula I化合物的方法。此外，该发明还提供了包含Formula I化合物的药物组合物，以及使用Formula I药物组合物治疗和预防与调节细胞中钙通道功能的RyR受体相关的疾病和疾病的方法。这些疾病包括但不限于心脏疾病、骨骼肌肉疾病、认知障碍和疾病、恶性高热、糖尿病和婴儿猝死综合征。心脏疾病包括但不限于心律不齐疾病、运动诱发的心律不齐疾病、猝死、运动诱发的猝死、充血性心力衰竭、慢性阻塞性肺疾病和高血压。心律不齐疾病和疾病包括运动诱发的心律不齐疾病，但不限于心房和心室心律失常、心房和心室颤动、心房和心室快速心律失常、心房和心室快速心跳、儿茶酚胺多形性心室心动过速（CPVT）及其运动诱发的变体。骨骼肌肉疾病包括但不限于骨骼肌疲劳、运动诱发的骨骼肌疲劳、肌肉萎缩、膀胱疾病和失禁。认知障碍和疾病包括但不限于阿尔茨海默病、各种记忆丧失形式和年龄相关的记忆丧失。

  公开号：

  US20070049572A1

文献信息

• Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
  申请人：Marks R. Andrew

  公开号：US20050215540A1

  公开（公告）日：2005-09-29

  The present invention provides methods for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject. The present invention further provides methods for treating and preventing atrial and ventricular cardiac arrhythmias, heart failure, and exercise-induced sudden cardiac death in a subject. Additionally, the present invention provides use of JTV-519 in a method for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject who has, or is a candidate for, atrial fibrillation. Also provided are uses of 1,4-benzothiazepine derivatives in methods for treating and preventing atrial and ventricular cardiac arrhythmias and heart failure in a subject, and for preventing exercise-induced sudden cardiac death. The present invention also provides methods for identifying agents for use in treating and preventing atrial fibrillation and heart failure, and agents identified by these methods.

  本发明提供了限制或预防受试者中RyR2结合FKBP12.6水平下降的方法。本发明进一步提供了治疗和预防受试者中心房和心室心律失常、心力衰竭以及运动诱发的突发性心脏死亡的方法。此外，本发明提供了在限制或预防受试者中RyR2结合FKBP12.6水平下降的方法中使用JTV-519的用途，该受试者患有或有可能患上心房颤动。还提供了1,4-苯并噻唑啉衍生物在治疗和预防受试者中心房和心室心律失常以及心力衰竭，以及预防运动诱发的突发性心脏死亡的方法中的用途。本发明还提供了用于识别用于治疗和预防心房颤动和心力衰竭的药剂的方法，以及通过这些方法识别的药剂。
• [EN] COMPOUNDS AND METHODS FOR MODULATING ACTIVITY OF CALCIUM RELEASE CHANNELS<br/>[FR] COMPOSÉS ET PROCÉDÉS DE MODULATION DE L'ACTIVITÉ DES CANAUX DE LIBÉRATION DE CALCIUM
  申请人：OREGON STATE

  公开号：WO2010120382A1

  公开（公告）日：2010-10-21

  The present teachings provide compounds of Formulae I and II: and and pharmaceutically acceptable salts, hydrates, complexes, esters, and prodrugs thereof, wherein R1, R1', R2, R2', R3, R3', and X are as defined herein. The present teachings also provide methods of making the compounds of formulae I and II, and methods of treating RyR-associated conditions, disorders, and diseases that include administering a therapeutically effective amount of a compound of formula I or II to a subject in need thereof. In addition, the present teachings relate to methods of reducing the open probability of a ryanodine receptor, and methods of reducing Ca2+ release across a ryanodine receptor (e.g., into the cytoplasm of a cell), by contacting a compound of formula I or II with a ryanodine receptor.

  本教学提供了Formulae I和II的化合物：以及其在药用上可接受的盐、水合物、络合物、酯和前药，其中R1、R1'、R2、R2'、R3、R3'和X的定义如本文所述。本教学还提供了制备Formulae I和II的化合物的方法，以及治疗与RyR相关的病症、紊乱和疾病的方法，包括向需要的受试者施用Formula I或II的化合物的治疗有效量。此外，本教学还涉及减少Ryanodine受体的开放概率的方法，以及通过与Ryanodine受体接触Formula I或II的化合物来减少Ca2+释放跨越Ryanodine受体（例如，进入细胞的细胞质）的方法。
• Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
  申请人：——

  公开号：US20040229781A1

  公开（公告）日：2004-11-18

  The present invention provides a method for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject, a method for treating or preventing exercise-induced cardiac arrhythmia in a subject, and a method for preventing exercise-induced sudden cardiac death in a subject. Also provided are uses of JTV-519 in these methods. The present invention further provides methods for identifying agents for use in preventing exercise-induced sudden cardiac death, as well as agents identified by such methods. Also provided are methods for preventing exercise-induced sudden cardiac death by administering these agents. Additionally, the present invention provides methods for synthesizing JTV-519, radio-labeled JTV-519, and 1,4-benzothiazepine intermediates and derivatives.

  本发明提供了一种限制或预防受试者中RyR2-结合FKBP12.6水平下降的方法，一种治疗或预防受试者运动引起的心律失常的方法，以及一种预防受试者运动引起的猝死的方法。此外，本发明还提供了JTV-519在这些方法中的用途。本发明还提供了一种用于识别用于预防运动引起的猝死的药剂的方法，以及由这些方法识别出的药剂。此外，本发明还提供了通过给予这些药剂预防运动引起的猝死的方法。此外，本发明还提供了合成JTV-519，放射性标记的JTV-519以及1,4-苯并噻唑中间体和衍生物的方法。
• NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RyR2)
  申请人：Marks Andrew Robert

  公开号：US20100152440A1

  公开（公告）日：2010-06-17

  The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBP12.6 in a subject; to prevent exercise-induced sudden cardiac death in a subject; and to treat or prevent heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia in a subject. The present invention further provides methods for identifying an agent that enhances binding of RyR2 and FKBP12.6, and agents identified by these methods. Additionally, the present invention provides methods for identifying agents for use in treating or preventing heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia, and in preventing exercise-induced sudden cardiac death. Also provided are agents identified by such methods.

  本发明提供了新颖的1,4-苯并噻唑啉中间体和衍生物，以及合成这些化合物的方法和检测这些化合物的方法。本发明还提供了使用这些新化合物限制或预防受试者中RyR2-结合FKBP12.6水平下降的方法；预防受试者运动引起的突发性心脏死亡的方法；以及治疗或预防受试者心力衰竭、心房颤动或运动引起的心脏心律失常的方法。本发明还提供了用于识别增强RyR2和FKBP12.6结合的试剂的方法和由这些方法识别的试剂。此外，本发明还提供了用于识别用于治疗或预防心力衰竭、心房颤动或运动引起的心脏心律失常以及预防运动引起的突发性心脏死亡的试剂的方法，以及由这些方法识别的试剂。
• Compounds And Methods For Modulating Activity Of Calcium Release Channels
  申请人：Abramson Jonathan J.

  公开号：US20120101085A1

  公开（公告）日：2012-04-26

  The present teachings provide compounds of Formulae I and II: and pharmaceutically acceptable salts, hydrates, complexes, esters, and prodrugs thereof, wherein R 1 , R 1′ , R 2 , R 2′ , R 3 , R 3′ , and X are as defined herein. The present teachings also provide methods of making the compounds of formulae I and II, and methods of treating RyR-associated conditions, disorders, and diseases that include administering a therapeutically effective amount of a compound of formula I or II to a subject in need thereof. In addition, the present teachings relate to methods of reducing the open probability of a ryanodine receptor, and methods of reducing Ca 2+ release across a ryanodine receptor (e.g., into the cytoplasm of a cell), by contacting a compound of formula I or II with a ryanodine receptor.

  本发明提供了公式I和II的化合物：以及其药学上可接受的盐，水合物，配合物，酯和前药，其中R1，R1'，R2，R2'，R3，R3'和X如本文所定义。本发明还提供了制备公式I和II化合物的方法，以及治疗与RyR相关的疾病和疾病的方法，包括向需要的受体中投与公式I或II的化合物的治疗有效量。此外，本发明涉及通过将公式I或II的化合物与Ryanodine受体接触，以降低Ryanodine受体的开放概率和减少Ca2+释放（例如进入细胞质）的方法。